Evaluation of PBMC distribution and TLR9 expression in patients with systemic lupus erythematosus

Iranian Journal of Allergy, Asthma and Immunology

Volumn 15, Issue 3, 2016, Pages 229-236

  Mortezagholi, Sahar ^a   Babaloo, Zohreh ^a   Rahimzadeh, Parisa ^a   Ghaedi, Mojgan ^a   Namdari, Hayedeh ^a   Assar, Shirin ^b   Mohamadabadi, Maryam Azimi ^a   Salehi, Eisa ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Autoimmunity; Lymphocyte; Monocyte; Systemic lupus erythematosus; Toll like receptor 9

Indexed keywords

CD14 ANTIGEN; CD19 ANTIGEN; CD56 ANTIGEN; TOLL LIKE RECEPTOR 9; TLR9 PROTEIN, HUMAN;

ADULT; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOCOMPETENT CELL; LYMPHOCYTE COUNT; MALE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MONOCYTE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; CLINICAL TRIAL; GENE EXPRESSION REGULATION; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL;

ADULT; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; TOLL-LIKE RECEPTOR 9;

EID: 84978700521     PISSN: 17351502     EISSN: 17355249     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Mok C, Lau C. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56(7):481-90.
2. Means TK, Luster AD. Toll-like receptor activation in the pathogenesis of systemic lupus erythematosus. Ann N Y Acad Sci 2005; 1062:242-51.
3. Crispín JC, Liossis S-NC, Kis Toth K, Lieberman LA, Kyttaris VC, Juang YT, et al. Pathogenesis of human systemic lupus erythematosus: Recent advances. Trends Mol Med 2010; 16(2):47-57.
4. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: A tutorial on B cell survival. Annu Rev Immunol 2003; 21(1):231-64.
5. Carroll MC. A protective role for innate immunity in systemic lupus erythematosus. Nat Rev Immunol 2004; 4(10):825-31.
6. McGaha TL, Sorrentino B, Ravetch JV. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 2005; 307(5709):590-3.
7. Marshak Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6(11):823-35.
8. Christensen SR, Shlomchik MJ, editors. Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin Immunol 2007; 19(1):11-23.
9. Guggino G, Giardina AR, Ciccia F, Triolo G, Dieli F, Sireci G. Are toll-like receptors and decoy receptors involved in the immunopathogenesis of systemic lupus erythematosus and lupus-like syndromes? Clin Dev Immunol 2011; 2012:135932.
10. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21(1):335-76.
11. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007; 13(5):543-51.
12. Kim WU, Sreih A, Bucala R. Toll-like receptors in systemic lupus erythematosus; prospects for therapeutic intervention. Autoimmun Rev 2009; 8(3):204-8.
13. Rahman AH, Eisenberg RA. The role of toll-like receptors in systemic lupus erythematosus. Springer Semin Immunopathol 2006; 28(2):131-43.
14. Liossis S, Ding XZ, Dennis GJ, Tsokos GC. Altered pattern of TCR/CD3-mediated protein- Tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J Clin Invest 1998; 101(7):1448-57.
15. Mak A, Kow NY. The pathology of T cells in systemic lupus erythematosus. J Immunol Res 2014; 2014.
16. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35(6):630-40.
17. Blanco P, Pitard V, Viallard JF, Taupin JL, Pellegrin JL, Moreau JF. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52(1):201-11.
18. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 2002; 195(1):125-33.
19. Park YW, Kee SJ, Cho YN, Lee EH, Lee HY, Kim EM, et al. Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum 2009; 60(6):1753-63.
20. Green M, Kennell A, Larche M, Seifert M, Isenberg D, Salaman M. Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients. Clin Exp Immunol 2005; 141(1):165-73.
21. Gonzalez Amaro R, Alcocer Varela J, Alarcon Segovia D. Natural killer cell activity in the systemic connective tissue diseases. J Rheumatol 1988; 15(8):1223-8.
22. Hervier B, Beziat V, Haroche J, Mathian A, Lebon P, Ghillani Dalbin P, et al. Phenotype and function of natural killer cells in systemic lupus erythematosus: Excess interferon-γ production in patients with active disease. Arthritis Rheum 2011; 63(6):1698-706.
23. Li Y, Lee PY, Reeves WH. Monocyte and macrophage abnormalities in systemic lupus erythematosus. Arch Immunol Ther Exp (Warsz) 2010; 58(5):355-64.
24. Byrne JC, Ní Gabhann J, Lazzari E, Mahony R, Smith S, Stacey K, et al. Genetics of SLE: functional relevance for monocytes/macrophages in disease. Clin Dev Immunol 2012; 2012:582252.
25. Klonowska Szymczyk A, Wolska A, Robak T, Cebula Obrzut B, Smolewski P, Robak E. Expression of toll-like receptors 3, 7, and 9 in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Mediators Inflamm 2014; 2014.
26. Wong C, Wong P, Tam L, Li E, Chen D, Lam C. Activation profile of Toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus. Clin Exp Immunol 2010; 159(1):11-22.
27. Komai Koma M, Jones L, Ogg GS, Xu D, Liew FY. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci U S A 2004; 101(9):3029-34.
28. Chuang TH, Ulevitch RJ. Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors. Nat Immunol 2004; 5(5):495-502.
29. Papadimitraki ED, Choulaki C, Koutala E, BertsiasTsatsanis C, Gergianaki I, et al. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: Implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 2006; 54(11):3601-11.
30. Migita K, Miyashita T, Maeda Y, Nakamura M, Yatsuhashi H, Kimura H, et al. Toll-like receptor expression in lupus peripheral blood mononuclear cells. J Rheumatol 2007; 34(3):493-500.
31. Nakano S, Morimoto S, Suzuki J, Nozawa K, Amano H, Tokano Y, et al. Role of pathogenic auto- Antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology 2008; 47(2):145-9.
32. Tian Z, Gershwin ME, Zhang C. Regulatory NK cells in autoimmune disease. J Autoimmun 2012; 39(3):206-15.
33. Richez C, Blanco P, Rifkin I, Moreau J-F, Schaeverbeke T. Role for toll-like receptors in autoimmune disease: The example of systemic lupus erythematosus. Joint Bone Spine 2011; 78(2):124-30.
34. Tadema H, Abdulahad WH, Stegeman CA, Kallenberg CG, Heeringa P. Increased expression of Toll-like receptors by monocytes and natural killer cells in ANCA- Associated vasculitis. PloS one 2011; 6(9):e24315.
35. Voynova EN, Skinner J, Bolland S. Expansion of an Atypical NK Cell Subset in Mouse Models of Systemic Lupus Erythematosus. J Immunol 2015; 194(4):1503-13.